高级检索
    杨广建, 王燕, 柯娥娥. 曙光乍现,值得期待——pan-HER抑制剂在HER2突变型非小细胞肺癌患者中的疗效及安全性[J]. 循证医学, 2022, 22(4): 202-206. DOI: 10.12019/j.issn.1671-5144.2022.04.003
    引用本文: 杨广建, 王燕, 柯娥娥. 曙光乍现,值得期待——pan-HER抑制剂在HER2突变型非小细胞肺癌患者中的疗效及安全性[J]. 循证医学, 2022, 22(4): 202-206. DOI: 10.12019/j.issn.1671-5144.2022.04.003
    shu
    YANG Guang-jian, WANG Yan, KE E-e. The Dawn Is Dawing, the Future Is Promising: Efficacy and Safety of pan-HER Inhibitors in Advanced Lung Adenocarcinoma With HER2 Mutations[J]. Journal of Evidence-Based Medicine, 2022, 22(4): 202-206. DOI: 10.12019/j.issn.1671-5144.2022.04.003
    Citation: YANG Guang-jian, WANG Yan, KE E-e. The Dawn Is Dawing, the Future Is Promising: Efficacy and Safety of pan-HER Inhibitors in Advanced Lung Adenocarcinoma With HER2 Mutations[J]. Journal of Evidence-Based Medicine, 2022, 22(4): 202-206. DOI: 10.12019/j.issn.1671-5144.2022.04.003
    shu

    曙光乍现,值得期待——pan-HER抑制剂在HER2突变型非小细胞肺癌患者中的疗效及安全性

    The Dawn Is Dawing, the Future Is Promising: Efficacy and Safety of pan-HER Inhibitors in Advanced Lung Adenocarcinoma With HER2 Mutations

      摘要
      • HTML全文
      • 参考文献(14)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回